查看完整行情页>>

|

货币单位:美元(USD)

Marker Therapeutics, Inc. (mrkr)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Frederick Gerald Wasserman Frederick Gerald Wasserman is a businessperson who has been at the head of 7 different companies and presently is Non-Executive Chairman for DLH Holdings Corp., Chairman at Marker Therapeutics, Inc. and President of FGW Partners LLC. In the past he held the position of President, Chief Operating & Financial Officer at Mitchell & Ness Nostalgia Co., Senior Vice President-Finance & Administration at Score Board, Inc., Chairman of MAM Software Group, Inc., President & Chief Financial Officer of Papel Giftware, Inc., President & Chief Financial Officer of Goebel of North America and Chief Compliance Officer of Wynnefield Capital Management LLC. Mr. Wasserman received an undergraduate degree from The Wharton School of the University of Pennsylvania.
Gerald Garrett Gerald Garrett is Vice President-Clinical Operations at Marker Therapeutics, Inc. Mr. Garrett received an undergraduate degree from Texas A&M University.
Mythili Koneru Mythili Koneru is Chief Medical Officer at Marker Therapeutics, Inc. In the past she occupied the position of Associate Vice President-Immuno-Oncology at Eli Lilly & Co. She received an undergraduate degree from The University of Chicago, a doctorate from New York University and a doctorate from Robert Wood Johnson Medical School.
Anthony H. Kim Currently, Anthony H. Kim holds the position of Chief Financial Officer at Marker Therapeutics, Inc. In the past Mr. Kim was Vice President-Health Group at Houlihan Lokey, Inc., Senior Vice President-Healthcare Group at Jefferies LLC and Executive Director-Healthcare Group at Nomura Securities International, Inc. Mr. Kim received an undergraduate degree from The University of Chicago and an MBA from UCLA Anderson School of Management.
Tsvetelina Pencheva Hoang Presently, Tsvetelina Pencheva Hoang holds the position of Vice President-Research & Development at Marker Therapeutics, Inc. Dr. Hoang previously occupied the position of Director-Translational Research at Bellicum Pharmaceuticals, Inc., Member of Memorial Sloan-Kettering Cancer Center, Member of The University of Texas M.D. Anderson Cancer Center and Member of The Phi Beta Kappa Society. She received an undergraduate degree and a graduate degree from Yale University and a doctorate from The Johns Hopkins University.
Monic Stuart Currently, Monic Stuart holds the position of Chief Medical Officer of Marker Therapeutics, Inc. Dr. Stuart received a doctorate and an undergraduate degree from the University of North Carolina at Chapel Hill and a graduate degree from The Johns Hopkins University.
Eliot M. Lurier Eliot M. Lurier holds the position of Chief Financial Officer at Tenax Therapeutics, Inc., Chief Financial Officer at Marker Therapeutics, Inc., Chief Financial Officer of Mustang Bio, Inc. and Chief Financial & Accounting Officer for SomaLogic, Inc. In his past career he held the position of Chief Financial Officer of Admetric Biochem, Inc., Chief Financial Officer of Danforth Advisors LLC, Chief Operating & Financial Officer at Bridge Pharmaceuticals, Inc., Chief Financial Officer, Treasurer & VP at BioMarin Pediatrics II, Inc., CFO, Treasurer & Head-Investor Relations at Interleukin Genetics, Inc., Chief Financial Officer & VP-Administration at NUCRYST Pharmaceuticals Corp., Auditor for Coopers & Lybrand Sp zoo and Chief Financial Officer of Joslin Diabetes Center, Inc. Eliot M. Lurier received an undergraduate degree from Syracuse University.
Michael J. Loiacono Michael J. Loiacono is Secretary, Treasurer & Chief Accounting Officer at Marker Therapeutics, Inc. Mr. Loiacono previously was Chief Financial & Accounting Officer for Global Axcess Corp., CFO, CAO & Investor Relations Contact at Global Axcess Corp., Vice President-Finance of Reach Services (USA), Inc., Controller & Finance Director at ITXC Corp., Vice President-Finance for InfiniRoute Networks, Inc., Head-Strategic Development at Fiduciary Trust Company International (13906) and Head-Strategic Development at FCTI, Inc. He received an undergraduate degree from Rutgers Business School.
Peter L. Hoang Peter L. Hoang occupies the position of President, Chief Executive Officer & Director at Marker Therapeutics, Inc. He is also on the board of Esperance Pharmaceuticals, Inc. In his past career he held the position of President & Chief Executive Officer for Tapimmune, Inc., Head-Mergers & Acquisitions at JPMorgan Chase & Co., Senior VP-Business Development & Strategy at Bellicum Pharmaceuticals, Inc., MD, Head-Healthcare Mergers & Acquisitions at CIT Group, Inc., Executive Director-Global Mergers & Acquisitions at Oppenheimer & Co., Inc., Head-Mergers & Acquisitions at Deutsche Bank Corp., Head-Mergers & Acquisitions at Merrill Lynch & Co., Inc. and Managing Director-Innovations at The University of Texas M.D. Anderson Cancer Center. Mr. Hoang received an undergraduate degree from Yale University and an MBA from UCLA Anderson School of Management.
Juan F. Vera Juan F. Vera founded AlloVir, Inc. and Marker Cell Therapy, Inc. Currently, he is President, CEO, CFO & Chief Accounting Officer at Marker Therapeutics, Inc. Dr. Vera is also Associate Professor at Baylor College of Medicine and Director & Chief Product Development Officer at AlloVir, Inc. Dr. Vera received a doctorate from Universidad El Bosque.
Norman David Eansor Presently, Norman David Eansor occupies the position of Independent Chairman for Marker Therapeutics, Inc. and President of Cyvek, Inc. He is also on the board of B-MoGen Biotechnologies, Inc. In the past he held the position of President-Bioproducts Business Unit at Cambrex Corp., President-Protein Sciences Segment at Bio-Techne Corp. and Managing Director at Novus Biologicals LLC (a subsidiary of Bio-Techne Corp.), President-Bioscience Division at Thermo Fisher Scientific, Inc., Vice President-Operations for Cardinal Health Corp. and Vice President-Pharmaceutical Operations at R.P. Scherer Corp. Norman David Eansor received an undergraduate degree from the University of Western Ontario and an MBA from the University of Windsor.
John R. Wilson Founder of AlloVir, Inc., Wilson Wolf Manufacturing Corp. and Marker Cell Therapy, Inc., John R. Wilson presently occupies the position of Chief Executive Officer at Wilson Wolf Manufacturing Corp. He is also on the board of Marker Therapeutics, Inc. (former Chief Executive Officer). In his past career Mr. Wilson held the position of Independent Non-Executive Director at AlloVir, Inc., Chief Executive Officer at Marker Cell Therapy, Inc. and Principal at Cellex Biosciences, Inc. Mr. Wilson received an undergraduate degree from Hamline University and an undergraduate degree from the University of Minnesota.
Katharine Knobil Katharine Knobil is on the board of Marker Therapeutics, Inc., Nimbus Therapeutics LLC and Pliant Therapeutics, Inc. and Member of The National Academies of Science. In her past career she held the position of Chief Medical Officer for Agilent Technologies, Inc., Chief Medical Officer, Head-Research & Development at Kaleido Biosciences, Inc. and Chief Medical Officer & Senior Vice President at GlaxoSmithKline LLC. Dr. Knobil received an undergraduate degree from Cornell University and a doctorate from The University of Texas Southwestern Medical Center.
Steven Arnote Elms Steven Arnote Elms is a businessperson who has been at the helm of 6 different companies and currently occupies the position of Chairman at ADMA Biologics, Inc., Chairman of Elevation Oncology, Inc. and Managing Partner at Aisling Capital LLC. Mr. Elms is also Managing Member at Aisling Capital Partners LLC and Director-INVO at Northwestern University and on the board of 5 other companies. In his past career Mr. Elms was Co-Chairman at LENSAR, Inc., Chairman at MAP Pharmaceuticals LLC, Chairman of Adams Respiratory Therapeutics, Inc., Chairman of Oculex Pharmaceuticals, Inc., Principal at Hambrecht & Quist Group, Inc., Consultant at Wilkerson Group, Principal at Marion Laboratories and Principal at Hambrecht & Quist. Mr. Elms received an undergraduate degree from Stanford University and an MBA from Kellogg School of Management.
David Laskow-Pooley David Laskow-Pooley is a businessperson who founded Pharmafor Ltd. and who has been the head of 6 different companies. Currently, he occupies the position of Chairman of Abliva AB, Chairman of Oxford Silk Phage Technologies Ltd., Chief Executive Officer & Director at Pharmafor Ltd. and Scientific Advisor at Q BioMed, Inc. He is also on the board of Marker Therapeutics, Inc., Ocean Broadband Networks (Shanghai) Co., Ltd., OBN (UK) Ltd. (former Chairman) and LREsystem Ltd. Dr. Laskow-Pooley previously was Chief Executive Officer & Director at LondonPharma Ltd., Chief Executive Officer at Surface Therapeutics Ltd. and Managing Director-UK Division at OSI Pharmaceuticals, Inc. He received an undergraduate degree from the University of Sunderland.